Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review

Umbrella review of 17 systematic reviews (211 pharmacoeconomic evaluations) on the cost-effectiveness of preemptive PGx genotyping

An umbrella review synthesizes 17 systematic reviews covering 211 pharmacoeconomic evaluations on the cost-effectiveness of preemptive pharmacogenetic testing. The main finding is striking: 71.1% of the 211 studies conclude that preemptive genotyping is cost-effective. The temporal trend is favorable, with an increasing proportion of positive studies from the emergence of the literature through October 2025. Data cover multiple genes and clinical contexts, with recognizable geographic limitations.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

This umbrella review of 211 pharmacoeconomic evaluations is the most comprehensive synthesis to date on the cost-effectiveness of preemptive genotyping. With 71% of studies positive and a growing trend, it provides public health policymakers with a solid argument for implementation. A reference article for institutional discussions on PGx genotyping reimbursement in France.